Among them, PD-L1 expression, TMB (≥10 mut/Mb), microsatellite instability (MSI-H), and mismatch repair deficiency (MMR) had been approved by health regulatory agencies as predictive biomarkers for immunotherapy in patients with NSCLC (55, 59–62). The gene discussed is CD274; the disease is non-small cell lung carcinoma.